anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Congenital diaphragmatic hernia (CDH) is a severe birth defect and a major cause of neonatal respiratory distress. Impacting ~2-3 in 10,000 births, CDH is associated with a high mortality rate, and long-term morbidity in survivors. Despite the significant impact of CDH, its etiology remains incompletely understood. In 2003, Greer et al. proposed the Retinoid Hypothesis, stating that the underlying cause of abnormal diaphragm development in CDH was related to altered retinoid signaling. In this review, we provide a comprehensive update to the Retinoid Hypothesis, discussing work published in support of this hypothesis from the past 20 years. This includes reviewing teratogenic and genetic models of CDH, lessons from the human genetics of CDH and epidemiological studies, as well as current gaps in the literature and important areas for future research. The Retinoid Hypothesis is one of the leading hypotheses to explain the etiology of CDH, as we continue to better understand the role of retinoid signaling in diaphragm development, we hope that this information can be used to improve CDH outcomes. IMPACT: This review provides a comprehensive update on the Retinoid Hypothesis, which links abnormal retinoic acid signaling to the etiology of congenital diaphragmatic hernia. The Retinoid Hypothesis was formulated in 2003. Twenty years later, we extensively review the literature in support of this hypothesis from both animal models and humans.
The invention discloses a gentle facial cleanser specially used for moisturization, which is prepared from the following raw materials comprising, by weight, 10-15 parts of isopropyl palmitate, 11-13 parts of coconut diethanolamide, 8-11 parts of olive oil, 4-6 parts of glycerol, 9-11 parts of aloe, 2-5 parts of sodium alginate, 5-8 parts of an extract liquid of chrysanthemum indicum, 1-3 parts of a water extract of rhodiola rosea, 2-4 parts of seaweed extract liquid, 2-3 parts of camellia seed oil, 4-6 parts of plant essential oil, 6-9 parts of a moisturizing factor, 7-9 parts of a skin caring component and 30-40 parts of pure water. The seaweed extract liquid includes alginic acid, coarse protein, various vitamins, enzymes and microelements. The olive oil and the camellia seed oil are natural cleansing components. The aloe has an itch relieving function. The glycerol has the effect of moisturizing skin. The extract liquid of chrysanthemum indicum and the water extract of rhodiola rosea both have the effect of caring and cleaning skin. The moisturizing factor enables skin to be moisturized, dry-free and more elastic. The skin caring component enables the skin to be more moisturized and glossy.
TTAX01 will be applied directly to the wound surface and fixed with sterile adhesive strips, plus a secondary foam dressing held in place by multi-layer compression bandaging. A single layer of the test article should cover the entire open surface of the wound. TTAX01 may overlap onto adjacent healthy tissue and must be fenestrated prior to or after fixture. The material is to be applied once every 4 weeks unless the wound shows evidence of healing, in which case product will be withheld; or, if the test article has been accidentally dislodged within 1-week post application, it may be replaced at the subsequent treatment visit.
A first subject of the present invention is an insoluble powder characterized in that a zeta-potential is a negative value. It is preferable that barium sulfate is a main ingredient in the insoluble powder. It is preferable that an average primary particle diameter is 3 to 100 μm, and an aspect ratio is 3 to 250 in the insoluble powder. It is preferable that the insoluble powder is a metal-doped barium sulfate powder obtained by reacting a barium ion and a sulfate ion in the presence of a metal ion. It is preferable that the metal ion is one or more selected from the group consisting of a lithium ion, a sodium ion and a zinc ion in the insoluble powder. A second subject of the present invention is a skin barrier function recovering powder, or a skin roughening preventing and improving powder, which comprises the aforementioned powder. A third subject of the present invention is a skin external composition characterized in that a content of the aforementioned powder is 1 to 40% by weight.
The major goal of translational research is to evaluate the efficacy and effectiveness of treatments and interventions that have emerged from exhaustive preclinical evidence. In 2007, a major clinical trial was started to investigate the impact of paravertebral analgesia on breast cancer recurrence. The trial was based on preclinical evidence demonstrating that spinal anesthesia suppressed metastatic dissemination by inhibiting surgical stress, boosting the immunological response, avoiding volatile anesthetics, and reducing opioid use. However, that trial and three more recent randomized trials with a total of 4,770 patients demonstrate that regional analgesia does not improve survival outcomes after breast, lung, and abdominal cancers. An obvious question is why there was an almost complete disconnect between the copious preclinical investigations suggesting benefit and robust clinical trials showing no benefit? The answer is complex but may result from preclinical research being mechanistically driven and based on reductionist models. Both basic scientists and clinical investigators underestimated the limitations of various preclinical models, leading to the apparently incorrect hypothesis that regional anesthesia reduces cancer recurrence. This article reviews factors that contributed to the discordance between the laboratory science, suggesting that regional analgesia might reduce cancer recurrence and clinical trials showing that it does not-and what can be learned from the disconnect.
A system for releasably connecting a plurality of interchangeable components in an assembly. The system includes a plurality of units and a plurality of interchangeable components capable of being releasably joined to one or more of the plurality of units. The plurality of units further includes a physical connecting system and a magnetic connecting system for relative positioning of at least one of the plurality of units with at least another one of the plurality of units. The physical connecting system includes a set of physical keys. The set of physical keys includes an indentation and projection on the surface of the unit. The magnetic connecting system includes a plurality of magnetic connectors housed in the interior housing of each of the plurality of units.
Treatment with dapagliflozin 10mg once daily orally. Treatment will start as soon as possible after initation of glucocorticoid pulse therapy for acute exacerbation COPD and will end when pulse therapy is finished (expected duration 10-14 days). In case of persistent glucose levels \> 12 mmol/l, subjects will receive escape treatment with sliding scale insulin.
Knee osteoarthritis is a chronic joint disease mainly characterized by cartilage degeneration. The treatment is challenging due to the lack of blood vessels and nerve supplies in cartilaginous tissue, causing a prominent limitation of regenerative capacity. Hence, we investigated the cellular promotional and anti-inflammatory effects of sericin, Bombyx mori-derived protein, on three-dimensional chondrogenic ATDC5 cell models. The results revealed that a high concentration of sericin promoted chondrogenic proliferation and differentiation and enhanced matrix production through the increment of glycosaminoglycans, COL2A1, COL X, and ALP expressions. SOX-9 and COL2A1 gene expressions were notably elevated in sericin treatment. The proteomic analysis demonstrated the upregulation of phosphoglycerate mutase 1 and triosephosphate isomerase, a glycolytic enzyme member, reflecting the proliferative enhancement of sericin. The differentiation capacity of sericin was indicated by the increased expressions of procollagen12a1, collagen10a1, rab1A, periostin, galectin-1, and collagen6a3 proteins. Sericin influenced the differentiation capacity via the TGF-β signaling pathway by upregulating Smad2 and Smad3 while downregulating Smad1, BMP2, and BMP4. Importantly, sericin exhibited an anti-inflammatory effect by reducing IL-1β, TNF-α, and MMP-1 expressions and accelerating COL2A1 production in the early inflammatory stage. In conclusion, sericin demonstrates potential in promoting chondrogenic proliferation and differentiation, enhancing cartilaginous matrix synthesis through glycolysis and TGF-β signaling pathways, and exhibiting anti-inflammatory properties.
The intervention group will target 150 minutes of moderate to vigorous aerobic physical activity and two days of strength training, consistent with the current physical activity recommendations. Participants will engage in 2 days per week of supervised activity at community facilities. These participants will be requested to engage in an additional 30 minutes of moderate to vigorous aerobic physical activity two days per week at home.
During the last two decades, the introduction of tyrosine kinase inhibitors (TKIs) to the therapy has changed the natural history of CML but progression into accelerated and blast phase (AP/BP) occurs in 3-5% of cases, especially in patients resistant to several lines of TKIs. In TKI-refractory patients in advanced phases, the only curative option is hematopoietic stem cell transplantation. We and others have shown the relevance of the expression of the Interleukin-2-Receptor α subunit (IL2RA/CD25) as a biomarker of CML progression, suggesting its potential use as a therapeutic target for CAR-based therapies. Here we show the development of a CAR-NK therapy model able to target efficiently a blast crisis cell line (K562). The design of the CAR was based on the scFv of the clinically approved anti-CD25 monoclonal antibody (Basiliximab). The CAR construct was integrated into NK92 cells resulting in the generation of CD25 CAR-NK92 cells. Target K562 cells were engineered by lentiviral gene transfer of CD25. In vitro functionality experiments and in vivo leukemogenicity experiments in NSG mice transplanted by K562-CD25 cells showed the efficacy and specificity of this strategy. These proof-of-concept studies could represent a first step for further development of this technology in refractory/relapsed (R/R) CML patients in BP as well as in R/R acute myeloblastic leukemias (AML).
<P>PROBLEM TO BE SOLVED: To obtain a swallowing auxiliary for medicines, which improves swallowing of various medicines, is convenient, can be an alternative to ordinary drinking water, and does not inhibit the effects of the medicines, and moreover a novel swallowing auxiliary which can be widely applied regardless of various kinds of medicines or various kinds of dosage forms and can further be applied to healthy food products and materials thereof.  <P>SOLUTION: This swallowing auxiliary is obtained by using granular jelly and the granular jelly can be manufactured by the following method (A) or (B). The method (A) comprises pushing out gelled jelly, obtained by gelling a gelling agent in the presence or in the absence of a coagulant, through a pore or a net, or cutting the gelled jelly. The method (B) comprises gelling a gelling agent by pouring or dripping it into a coagulant solution. Jelly in the granular form gives remarkable effects that operations of putting a medicine thereinto or mixing a medicine therewith are carried out more smoothly and that a medicine is taken into the mouth more easily and swallowed more easily compared with the case of jelly which is not in the form of a granule though having the same formulation. The swallowing auxiliary can be applied not only to medicines but also to healthy food products and materials thereof.  <P>COPYRIGHT: (C)2004,JPO
<P>PROBLEM TO BE SOLVED: To provide a new peritoneal deterioration inhibitor, a peritoneal dialytic fluid and a method for peritoneal dialysis, inhibiting peritoneal deterioration using a rare saccharide.  <P>SOLUTION: The peritoneal deterioration inhibitor characterized by containing a rare saccharide is provided, wherein the rare saccharide is selected from the group consisting of d-psicose, L-psicose, D-allose, L-sorbose, D-fructose, L-tagatose, D-sorbose, L-fructose and D-tagatose. This peritoneal deterioration inhibitor is characterized by containing, in addition, glucose. This inhibitor is to be used by compounding in a peritoneal dialytic fluid. The peritoneal dialytic fluid is characterized by containing the above inhibitor. This peritoneal dialytic fluid is characterized by containing, in addition, glucose and an electrolyte. The method for peritoneal dialysis is characterized by involving using a dialytic fluid containing an effective amount of the above rare saccharide or its salt.  <P>COPYRIGHT: (C)2010,JPO&INPIT
PURPOSE:To attain the successive reading of entire inspection pictures, and to minimize a workload by comparing and classifying plural inputted diagnostic results for each medical inspection data, and outputting the identified informa tion. CONSTITUTION:Information related with medical interview or history is inputted from a medical interview information inputting device H1, and picture data being one kind of the medical inspection data are inputted from a picture collector 1A. In a data base DB to which the picture data are inputted, each picture data are CAD-processed, abnormality detection is operated, and an abnormality data chart being the result is prepared. On the other hand, the picture data or the medical interview information or the like are transmitted from the data base DB to a word station WS, the picture data are displayed, and read by a doctor. Then, the doctor prepares and inputs a view data chart being the read result of each picture data. When the reading by the doctor is ended, the view data chart and the abnormality data chart are compared and classified, an abnormality detection result list being the result is prepared, and outputted for each classification.
A point-of-care medical testing system integrated with a patient monitor is disclosed. The system may include a microfluidic cartridge configured to receive a blood sample and generate a sensory signal dependent on a concentration of a biomarker in the blood sample. A cartridge reading assembly receives the microfluidic cartridge. The cartridge reading assembly includes a processing unit and a memory coupled with the processing unit. The memory stores executable instructions to cause the processing unit to receive the sensory signal, correlate the received sensory signal with the concentration of the biomarker in the blood sample, and produce an output representative of the concentration of the biomarker in the blood sample. The cartridge reading assembly is coupled to the patient monitor and configured to send the output to the patient monitor.
PROBLEM TO BE SOLVED: To obtain the subject therapeutic agent, comprising an antithrombin-III derived from a human as an active ingredient and having effects of reduction in lowering in excretion of bile and leakage of hepatic enzyme such as a glutamic-pyruvic transaminase(GPT) on mammals suffering from ischemic reperfusion disorder. SOLUTION: This therapeutic agent for ischemic reperfusion hepatopathy comprises an antithrombin-III (AT-III) derived from a human as an active ingredient. The AT-III is obtained by purification from human blood; however, blood negative to an HBs antigen and an antiHIV antibody is preferably used as the blood. A fraction IV-1, a supernatant I, etc., prepared by, e.g. a Cohn cold ethanol method can be used as a starting raw material for preparing the AT-III. The objective therapeutic agent is preferably used by preparing the AT-III as a freeze-dried product and formulating the AT-III into a solution at 1-100 AT-III units (one unit is the amount of the AT-III in 1ml normal human blood plasma)/ml with distilled water for injection at the time of use.  The therapeutic agent is preferably intravenously administered in a daily dose of 10-500 units/kg body weight in one or several divided portions.
Subjects will receive ASP1235 (AGS62P1) as an intravenous infusion once every three weeks (Q3W) to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose. A cycle is 21 days.
Bitter gourd (BG) (Momordica charantia), is a highly nutritive vegetable from the cucumber family. The objective is to assess the impact of 4-week BG supplementation on blood glucose levels and glucose tolerance in subjects with an impaired fasting glucose or with an impaired glucose tolerance and to evaluate how BG supplements modulate glucose response curves during meal intake. The study is a randomized, cross-over, double blind, controlled trial in which study participants will receive two 4-week interventions with a washout period of 4 weeks between interventions. Study subjects will visit the research facility before and after each intervention period for a test day. In the third intervention week participants are provided with a 3-day controlled diet and glucose responses will be monitored via a continuous glucose monitoring device. The intervention will be a 4-week intervention with 2.4g/d dried bitter-gourd supplements and a reference intervention with 2.4g/d dried cucumber supplements. The main study parameter is fasting levels of plasma glucose and 2hour plasma glucose after a 75-gram OGTT.
The shoulder brace (Cosmedical, Mauá, SP, Brazil) contains 159 red LEDs and 159 infrared LEDs interspersed. The PBM group (standard physical therapy combined with active PBM). Participants will apply PBM at home daily for 10 minutes using a device containing 318 light-emitting diodes (LEDs), with 159 LEDs at 660 nm (28.5 mW; 12 J/cm2; 17 J per LED) and 159 LEDs at 850 nm (23 mW; 10 J/cm2; 14 J per LED). PBM and physical therapy sessions (30 minutes, twice a week) will be conducted over 12 weeks.
Urolithin A (UroA), a dietary phytochemical, is produced by gut bacteria from fruits rich in natural polyphenols ellagitannins (ETs). The efficiency of ETs metabolism to UroA in humans depends on gut microbiota. UroA has shown a variety of pharmacological activities. In this study we investigated the effects of UroA on atherosclerotic lesion development and stability. Apolipoprotein E-deficient (ApoE-/-) mice were fed a high-fat and high-cholesterol diet for 3 months to establish atherosclerosis model. Meanwhile the mice were administered UroA (50 mg·kg-1·d-1, i.g.). We showed that UroA administration significantly decreased diet-induced atherosclerotic lesions in brachiocephalic arteries, macrophage content in plaques, expression of endothelial adhesion molecules, intraplaque hemorrhage and size of necrotic core, while increased the expression of smooth muscle actin and the thickness of fibrous cap, implying features of plaque stabilization. The underlying mechanisms were elucidated using TNF-α-stimulated human endothelial cells. Pretreatment with UroA (10, 25, 50 μM) dose-dependently inhibited TNF-α-induced endothelial cell activation and monocyte adhesion. However, the anti-inflammatory effects of UroA in TNF-α-stimulated human umbilical vein endothelial cells (HUVECs) were independent of NF-κB p65 pathway. We conducted RNA-sequencing profiling analysis to identify the differential expression of genes (DEGs) associated with vascular function, inflammatory responses, cell adhesion and thrombosis in UroA-pretreated HUVECs. Human disease enrichment analysis revealed that the DEGs were significantly correlated with cardiovascular diseases. We demonstrated that UroA pretreatment mitigated endothelial inflammation by promoting NO production and decreasing YAP/TAZ protein expression and TEAD transcriptional activity in TNF-α-stimulated HUVECs. On the other hand, we found that UroA administration modulated the transcription and cleavage of lipogenic transcription factors SREBP1/2 in the liver to ameliorate cholesterol metabolism in ApoE-/- mice. This study provides an experimental basis for new dietary therapeutic option to prevent atherosclerosis.
Pregnant women in the experimental group will be given 4 sessions Solution-Oriented Approach program, starting at the 32th week of pregnancy. Pregnants in the experimental group will be administered the Wijma Birth Expectation/Experience Scale (W-DEQ-A) and Pregnancy Psychosocial Health Assessment Scale (PPHAS) before the intervention. After the program is completed, a training booklet will be provided for pregnant women and (W-DEQ-A) and PPHAS will be applied again. With pregnant women, 37-40. between gestational weeks, they will be contacted again, face-to-face interview method (W-DEQ-A) and PPHAS again will be evaluated. The pregnant women will inform the researcher by phone after the delivery and the researcher will visit the hospital within the first 24 hours after the delivery to evaluate the mothers' birth fear levels Scale (W-DEQ-B). At the end of the first postpartum week, the postnatal senses of security of the mothers will be evaluated by telephone follow-up counseling.
Although fracture-related infection (FRI) is a serious complication following bone fractures, a comprehensive definition and diagnostic criteria have only emerged in recent years. According to this consensus definition, the diagnosis of FRI is based on preoperative and intraoperative suggestive or confirmatory criteria. Serum markers, histology, and microbiological cultures are considered to play a crucial role in the FRI diagnostic pathway. However, at the time of publication of the FRI consensus definition in 2018 and its update in 2020, limited data was available on the accuracy of these diagnostic methods. This review aims to provide an overview of recent publications and discuss whether new evidence has been obtained regarding the value of these current diagnostic techniques. Meanwhile, several studies have confirmed the limited prognostic value of C-reactive protein, erythrocyte sedimentation ratio, and white blood cell count. Other serologic markers for preoperative diagnosis of FRI with promising diagnostic performance are d-dimer, plasma fibrinogen, platelet count to mean platelet volume ratio, and a risk prediction model that includes soft tissue injury type and fracture complexity in addition to blood markers. However, their true diagnostic value in daily clinical practice needs to be investigated in further studies. Data on histology in FRI diagnosis is still limited, but its potential as a confirmatory criterion seems to lie in its high specificity. Recent studies indicate that tissue culture exhibits moderate sensitivity and high specificity, with sensitivity improvements achieved by sampling of five specimens and long-term culture. Implant sonication also appears to enhance the sensitivity of culture and the detection rate of polymicrobial infections. In conclusion, the true value of diagnostic techniques is difficult to assess, in part because it is measured against a gold standard that is itself imperfect and still evolving, but also because of methodological differences in sample processing or the use of different thresholds. Nevertheless, this review has identified that the value of current diagnostic techniques is high when used in combination. To draw more accurate conclusions about the value of serum markers, histology, and culture including sonication, future studies should be prospective and utilize a greater standardization in sampling and methodological protocols.